Kornimate/medical-research-clean huggingface dataset:
natriuretic brain pro-peptid changes in patients with chronic heart failure within a cardiac rehabilitation program

Conditions: Chronic Heart Failure

Summary: evaluate pro-bnp levels, oxygen consumption, functional class, and quality of life in patients with chronic heart failure after participating in an exercise program and compare them baseline and 2 months, with another group who underwent an educational program.

clinical controlled trial with a double blinded with a aleatory number sequence as the randomization method, patients will be assigned to one of two groups, intervention program (supervises exercise program) and control group (community based exercise)

Eligibility criteria:
inclusion criteria: * patients older than 18 years, diagnosed with heart failure (nyha) ii-iv for more than six months exclusion criteria: * patients with nyha functional class i, who had attended a cardiac rehabilitation program previously, patients with decompensated diabetes mellitus, hypertension difficult to control, ischemic heart disease in the last month, prior pulmonary embolism, chronic obstructive pulmonary disease, restrictive lung disease , aortic stenosis, new episode of atrial fibrillation and musculoskeletal diseases that limit the performance of physical activity

Keywords: chronic heart failure cardiac rehabilitation exercise natriuretic brain pro-peptid
compare the efficacy of aloe vera mouthwash with non- alcoholic chlorhexidine mouthwash on periodontal diseases

Conditions: Periodontal Diseases

Summary: aim: to compare the efficacy of aloe vera and non-alcoholic chlorhexidine mouthwash in the treatment of periodontal diseases. methods \&material: 32 patients were selected, the following periodontal parameters were recorded at baseline, and after recording all the parameters at the baseline, scaling, root planning, and polishing are done for all the patients participating in the study. oral hygiene instructions were given that included brushing twice a day with a soft brush, after 2 weeks, patients in the study, were randomly (balanced block randomization) equal divided into 2 groups; group a: mouthwash aloe vera (alodent co. uk) for each patient, group b: non-alcoholic chlorhexidine (perio-kin, livar co. spain) 10 ml by patients routinely washed two times in one day for about 30 seconds and lasts for 15 days, then every 7 days periodontal parameters, and at the end of 2 weeks (days 0, 7, 15) clinical changes are evaluated.

eligible participants were 32 adult patients treated for chronic periodontitis and participating in a supportive periodontal therapy program at the department of periodontology of the dental clinic of the islamic azad university, dental branch of tehran were included in the current study; recruitment of participants started july 2014 and ended may 2015. the study met the criteria of the helsinki declaration of 1975, revised in 2008. the survey plan was reviewed and sanctioned, approved by the ethics commission of the institutional ethical committee and review board of the deputy of research, school of dentistry. all subjects received the oral and written explanation of the intent of the survey and signed an informed consent after receiving detailed information about the purpose, the benefits, and the possible risks associated with the trial. individuals satisfying the following entry criteria were recruited: * diagnosed suffering from initial (early) to moderate chronic periodontitis; * adult patients, more than 28 years old with at least 20 remaining teeth and at least three teeth in each quadrant; * the presence of at least two residual sites with a probing pocket depth (ppd\>4 mm in two opposite quadrants, which showed bleeding upon probing, radiographically comparable amount of periodontal breakdown and good matching in tooth type, also clinical and minimal radiographic signs of initial (early) to moderate (clinical attachment level of 1 to 3mm.

Eligibility criteria:
inclusion criteria: * presence of two periodontal sites located on the same side pocket depth 4 mm or more. * chronic periodontitis patients. exclusion criteria: * orthodontic treatment. * use removal denture. * presence of vertical bone defect. * use of medicine therapy within the 3 months prior to the study. * allergy to chlorhexidine and aloe vera. * smoking. * systemic diseases that could influence the course of periodontal disease. * pregnancy and lactation. * aggressive periodontitis. * furcation involvement. * periodontal therapy 6 months prior to the study. * extensive caries.
context-aware mobile intervention for social recovery in serious mental illness

Conditions: Schizophrenia; Schizoaffective Disorder; Mood Disorder, Psychotic

Summary: this open trial will test a new technology-supported blended intervention, mobile social interaction therapy by exposure (msite), that targets social engagement in consumers with serious mental illness.

social isolation is common in serious mental illness and has a profound negative impact on recovery. this study evaluates a new technology-supported blended intervention, mobile social interaction therapy by exposure (msite), that targets social behavior, and it also validates several new techniques for measuring social behavior. msite blends brief in-person psychotherapy with context-triggered mobile smartphone intervention and remote telephone coaching. the investigators will conduct an open trial of msite, evaluating whether the intervention leads to clinically significant changes in the frequency of social interactions. the investigators will also determine the dose of app plus remote coaching necessary to achieve this effect, by evaluating change at 12, 18, or 24 weeks. if found to be effective, a scalable intervention that reduces social isolation in serious mental illness would have significant personal, societal, and economic impact.

Eligibility criteria:
inclusion criteria: 1. voluntary informed consent to participate and capacity to consent; 2. age 18 to 65; 3. dsm-5 diagnosis of schizophrenia, schizoaffective, bipolar i disorder or major depression with history of psychosis based on a scid-5 interview and available medical record review; 4. minimum level of social avoidance defined by a score of ≥ 2 on the scale for the assessment of negative symptoms (sans) asociality item; 5. ≥ 6th grade reading level on the wide range achievement test-4 reading subtest (to read therapy workbook). exclusion criteria: 1. prior cbt in the past 2 years; 2. greater than moderate disorganization on the panss (p2- disorganization item \>5); 3. dsm-5 alcohol or substance dependence in past 3 months based on the scid; 4. level of care required interferes with outpatient therapy (e.g., hospitalized; severe medical illness) 5. unable to adequately see or manually manipulate a phone; 6. resident of an integrated housing facility that also provides treatment services.
oncology care pathway's modifications impact during covid-19 pandemic : the oncocare-cov study

Conditions: Cancer

Summary: in december 2019, sars-cov2 and its clinical manifestations, covid-19, appeared in china and caused a pandemic. it led decision makers to prioritize emergency and intensive care dedicated to infection management. other conditions, such as cancer screening, diagnosis, and treatment, may have been delayed during the containment period. consequences of this "distraction effect" are being.

quantitative monthly data were analyzed from january 1, 2019 to may 31, 2020 in two french tertiary care center (university hospital and godinot cancer institute in reims) and in a third center in the french epicenter (colmar hospital). oncologic activity indicators were extracted using oncologic electronic file, international statistical classification of diseases and related health problems, tenth revision (icd-10) and nation-wide procedure codes (ccam). the monthly number of different steps of oncology care pathway (screening, diagnosis and treatment) were collected: faecal immunochemical testing (fit), mammography, histopathological and biomolecular/genetics analysis, nuclear medicine imaging, oncogeriatric evaluations, multidisciplinary tumor board meetings and files reviewed by meeting including first presentations, given personalized care program, medical announcement and reformulation nursing consultations, inserted central venous catheters, chemotherapy prepared and administered in chemotherapy day care, carcinologic surgeries and radiotherapy courses.

Eligibility criteria:
inclusion criteria: * every adult patient entering an oncology care pathway between 01/01/2019 and 31/12/2020 exclusion criteria: * \<18 yo
immunity to yellow fever in hiv-infected patients 10 years after a primary anti-yellow fever vaccination

Conditions: HIV Infections; Yellow Fever

Summary: anrs 0146s novaaten study aims to determine the vaccine responses in the participants of the anrs ep46 novaa trial 10 years after a primary anti-yellow fever vaccination

the vaccine responses will be determined with the measurement of the neutralizing antibody titers using the neutralization tests prnt and pseudo type acn 400 to m120 (ten years) in the participants of the anrs ep 46 novaa trial, vih+ and controls naïve to previous vaccination ten years after a primary anti-yellow fever vaccination.

Eligibility criteria:
inclusion criteria: * subjects included in the anrs ep 46 novaa trial: * 40 hiv positive subjects from consultations for infectious diseases and travel medicine centers at saint-louis, cochin-pasteur and bichat hospitals (on haart for at least one year and not modified in the 3 months preceding the pre-inclusion visit, cd4 \> 350/mm3 and a viral load \<50 copies / ml for at least 6 months). * 20 hiv negative subjects from the consultation of travelers from saint-louis, bichat and cochin-pasteur hospitals. * subjects agreeing to be monitored according to the terms of the protocol. * subjects affiliated to a social security scheme or beneficiaries of such a scheme. * signature of informed consent. exclusion criteria: * non-volunteers for the 10-year follow-up * subject under curatorship, guardianship or safeguard of justice.
a multicenter, prospective study of perioperative finotonlimab combined with bevacizumab in resectable hepatocellular carcinoma patients with high-risk factors for recurrence

Conditions: HCC

Summary: for patients with early- to mid-stage hepatocellular carcinoma (hcc), the five-year postoperative recurrence and metastasis rate remains as high as 70%, significantly impacting patient prognosis.therefore, perioperative therapy may be considered for hcc patients with these high-risk features .


Eligibility criteria:
inclusion criteria: 1. - informed consent voluntarily signed informed consent after full understanding of the study, with commitment to comply with all protocol requirements and assessment schedules. 2. age 18-75 years inclusive. 3. diagnosis histologically/cytologically confirmed hepatocellular carcinoma (hcc) or clinically diagnosed hcc per 2024 chinese guidelines for primary liver cancer. 4. tumor status meets one of the following: multifocal tumors (2-4 lesions) single lesion \>5 cm in longest diameter stage iiia hcc with vp1/vp2/vp3 portal vein tumor thrombus 5. resectability technically amenable to curative resection per surgeon assessment. 6. liver function child-pugh class a. 7. performance status ecog ps 0-1. 8. prior therapy no previous systemic treatment for hcc. 9. measurable disease ≥1 radiologically measurable lesion per mrecist. 10. organ function (1) hematological: anc ≥1.5×10⁹/l hemoglobin ≥90 g/l platelets ≥50×10⁹/l (2) hepatic: total bilirubin ≤1.5×uln ast/alt ≤2.5×uln albumin ≥28 g/l (3) coagulation: inr ≤2.3 or pt prolongation ≤3 sec vs control (4) renal: egfr \>90 ml/min/1.73m² (ckd-epi) 11. contraception women of childbearing potential: negative serum pregnancy test within 7 days prior to enrollment. all subjects: use highly effective contraception during treatment and for 180 days post-last dose. exclusion criteria: 1. pregnancy/lactation women who are pregnant or breastfeeding. 2. concurrent malignancy history of other malignancies within 5 years except: 3. curatively treated basal cell carcinoma cervical carcinoma in situ papillary thyroid carcinoma 4. drug hypersensitivity known allergy to finolizumab, bevacizumab, or their excipients. bleeding risk history of upper gi bleeding or active hemorrhagic disorders. 5. uncontrolled cardiac disease clinically significant cardiac conditions including: nyha class ii+ heart failure unstable angina myocardial infarction within 1 year clinically significant arrhythmias requiring intervention 6. autoimmune disorders active autoimmune diseases or history of autoimmune disorders. 7. immunodeficiency immunodeficiency conditions including: hiv positive status primary/secondary immunodeficiency history of organ/bone marrow transplantation 8. psychiatric conditions severe psychiatric disorders or substance abuse involving psychotropic drugs. 9. uncontrolled comorbidities severe uncontrolled recurrent infections or other significant uncontrolled comorbidities. 10. investigator discretion any condition deemed ineligible by the investigator.

Keywords: adjuvant regimen tace combined with targeted-immunotherapy
protective effect of sivelestat sodium on ards in patients with sepsis

Conditions: ARDS

Summary: sivelestat sodium has been approved for use in patients with sirs and ali, but whether it can protect patients with sepsis from developing ards remains unknown.the aim of this study was to determine whether sivelestat sodium has a protective effect on ards in patients with sepsis.

the study was conducted in accordance with good clinical practice and with the guidelines set out in the declaration of helsinki. after approval from local and national ethics committees, patients from 3 centers in china were recruited. all patients were randomized, in a double-blind manner, to receive either sivelestat sodium regimen or a placebo regimen for 1- 7 days in icu. the aim of this study was to determine whether sivelestat sodium has a protective effect on ards in patients with sepsis.

Eligibility criteria:
inclusion criteria: * within 24 hours after admission, sepsis 3.0 diagnostic criteria were met; * the patients or their family members fully understand the purpose and significance of the trial, voluntarily participate in the clinical trial, and sign the informed consent. exclusion criteria: * patients with ards were identified at the time of admission; * patients who explicitly refused mechanical ventilation; * patients with 3 or more extrapulmonary organ injuries and organ failure(single organ sofa score ≥ 3); * patients who need home oxygen therapy or with home mechanical ventilation (by tracheotomy or noninvasive ventilation, but excluding cpap / bipap, only for patients with obstructive sleep apnea); * the patient whose expected survival time was less than 48 hours; * pregnant women and lactating women; * other conditions judged by the researcher not suitable for inclusion.

Keywords: sepsis respiratory failure ards efficacy sivelestat sodium
study comparing coristina® d to resfenol® in the symptomatic treatment of common cold

Conditions: Cold

Summary: the primary objective of this study is to evaluate the non-inferiority of coristina® d in the symptomatic treatment of the common cold compared to resfenol® comparator.

eligible patients must sign the informed consent form and they will be between 18 and 60 years old and common cold symptoms for no more than 72 hours. it will be recruited for this study 366 patients, 183 patients per group. it is estimated that the total number of patients can be recruited in 4 to 6 months from the regulatory approval of the study. the patient will stay in the study approximately 7 to 10 days (including screening visit / randomization, telephone contact in 3 to 5 days after randomization and final visit from 1 to 3 days after last dose). study medication (coristina d and resfenol) will be provided by the sponsor and will be appropriately labeled for the clinical study, containing the sponsor information, the trial identification, expiration date, batch and storage conditions

Eligibility criteria:
inclusion criteria: 1. sign and date the informed consent form; 2. age between 18 and 60 years old; 3. symptoms of common cold not exceeding 72 hours must be present; 4. it will be considered symptoms of the common cold the presence of at least 2 of the 10 symptoms following: runny nose, sneezing, nasal congestion, headache, myalgia, throat discomfort or sore throat, hoarseness, cough or fever. each of the symptoms listed above will receive a score by likert scale (no symptom = 0, mild symptoms = 1, moderate symptoms = 2, intense symptoms = 3). the minimum total is 0 and maximum one is 30, which included patients with score higher or equal to 4 points. exclusion criteria: 1. presence of suggestive symptoms or prior diagnosis requiring regular and continuous treatment of allergic rhinitis or asthma in the last 2 years; 2. chronic disease of any kind that is contraindicate the participation of the patient based on the opinion of investigator; 3. hypersensitivity or contraindication to use of components of the study medications; 4. pregnant or women of childbearing age without adequate contraception; 5. use of other anti-influenza drugs programmed during the study or for the last 5 days; 6. regular active smokers (more than 3 cigarettes a day); 7. participation in another clinical study in less than one year (unless justified benefit by the investigator).

Keywords: common cold treatment
study of the effects of artificial tears on the response to the latanoprost punctal plug delivery system in subjects with ocular hypertension or open-angle glaucoma

Conditions: Glaucoma; Ocular Hypertension

Summary: the purpose of this study is to determine the effect of artificial tears preserved with benzalkonium chloride (at-bak) on the iop response to the l-ppds and to evaluate the safety of the l-ppds in subjects with oh or oag following treatment.


Eligibility criteria:
inclusion criteria: * over 18 years with ocular hypertension or open-angle glaucoma * subjects who have a best-corrected visual acuity of 20/100 or better exclusion criteria: * subjects who wear contact lenses * uncontrolled medical conditions * subjects with a known sensitivity to latanoprost, bak, or any other products required for the study * subjects requiring chronic topical artificial tears, lubricants, and/or requiring any other chronic topical medications.

Keywords: glaucoma ocular hypertension
screening and identification of ovarian cancers

Conditions: Ovarian Cancer

Summary: ovarian cancer is the first mortality rate of gynecologic malignancies. the incidence of ovarian cancer increased in recent 10 years and it has become the ninth cause of malignancies in the women in taiwan. from the above-mentioned data, ovarian cancer indeed is a disease that should be respected, however, there were only few of research work focusing on it in taiwan. despite the widespread use of aggressive cytoreductive surgery and the introduction of chemotherapy regimens, the overall survival has changed little over the last two decades. the basic problem in treating epithelial ovarian cancer is that once it has spread beyond the ovary, it is exceedingly difficult to control and ultimately to cure. more than 70% of ovarian cancer patients were advanced stage when diagnosed. to study the mechanisms of carcinogenesis, progression, and metastasis of ovarian cancer will help us understand this disease and develop new treatment strategies for ovarian cancer in the future. we have established an ascites-generating intraperitoneal tumor cell line-wf3 in the mouse model in our previous two-year project of nsc grant (grant number (nsc90-2314-b-002-457 and nsc91-2341-b-002-315). our group found that, mesothelin, this molecule is highly related with the carcinogenesis, tumor progression and tumor metastasis in our animal model and human cancer tissues. to further evaluate the role of mesothelin in ovarian cancer and elucidate the potential of mesothelin as a target antigen for immunotherapy,

methods: all of the patients received four to six courses of adjuvant platinum-containing chemotherapy. histologic grading was according to international union against cancer criteria (28). the stage of disease was classified according to the international federation of gynecology and obstetrics (figo, 1987). pelvic and paraaortic lymph node samplings will be performed, if the disease will be confined to within the ovary or will be without a ruptured capsule. the histopathologic data, including histologic type and histologic grade, will be evaluated by a certified pathologist. the maximal diameter of the residual tumor after surgery will be also recorded. all patients will be followed up at 3-month intervals.

Eligibility criteria:
inclusion criteria: * patients with ovarian carcinoma who undergo hysterectomy, bilateral oophorectomy and tubal resection, omentectomy, and appendectomy will be enrolled and the clinical data will be obtained from our hospital. exclusion criteria: * none
brain and cognitive function of patients with rpd

Conditions: Missing Posterior Occlusal Contact

Summary: to evaluate the influence of restoring lost posterior occlusal contacts with removable partial denture (rpd) on the brain activity and cognitive function in controlled type 2 diabetic patients


Eligibility criteria:
inclusion criteria: * loss of posterior occlusal contact unilaterally or bilaterally in both maxilla and mandible. * no previous partial dentures experience. * nonsmokers. * skeletally angle's class i. * controlled type 2 diabetes. exclusion criteria: * history of brain diseases (e.g. cerebral infarction, and alzheimer's). * neuromuscular disorders. * temporomandibular joint disorder. * psychiatric illness. * participants with parafunctional oral habits.

Keywords: removable partial dentures electro-encephalogram mini mental state examination controlled type 2 diabetes.
effect of modified 45-degree head-up tilt position in cesarean operation to the success of spinal anesthesia

Conditions: Regional Anesthesia Morbidity

Summary: the success of the application of spinal block in 3 different application as the sitting position, side decubitus position and 45 degrees head upside side decubitus position will be evaluated.

180 patients in asa i-ii risk group between the ages of 18-50 will be included in the study.the success of the application of spinal block in 3 different application as the sitting position, side decubitus position and 45 degrees head upside side decubitus position will be evaluated. anatomical features of height, weight, block application of the patients will be recorded.

Eligibility criteria:
inclusion criteria: * caesarean section * 18-50 years old * asa i-ii risk exclusion criteria: * heart failure * patient's refusal * thrombocytopenia * coagulation disorder * heart valve diseases

Keywords: sitting position lateral decubitus position spinal block